ClinicalTrials.gg
Active, not recruitingNCT03127995HYPOG-01Updated Nov 20, 2026Results posted

Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence

An interventional study of HYPOFRACTIONATED and NORMOFRACTIONATED in Breast Cancer Female, sponsored by UNICANCER. Active, not recruiting at 28 sites in France. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by UNICANCER · Not applicable, Interventional, and Other

How we know

Updated Nov 20, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,265
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Breast Neoplasms by UNICANCER — 15 open to participants now, 27 under way, 7 of them phase 3. Breast Neoplasms · UNICANCER.

Enrollment
12th of 59
1,265 · median 170
Started
2016
with 2 others
No phase
14 of 64
2 open now
Primary completion
2022-12
later than 2 of 26 live
Registered
33rd of 64
by date

Among the 64 studies in Breast Neoplasms by UNICANCER, this one is the 12th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2016, is one of 14 with no phase, reaches primary completion later than 2 of the 26 other live ones, and was the 33rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 64 studies in Breast Neoplasms by UNICANCER are open now, in 9 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by UNICANCER, or all of them as a file.
02

Study summary

The standard treatment of localized breast cancers consists of surgical removal of the tumor at the breast or removal of the entire breast and lymph nodes (sentinel lymph node and / or axillary dissection) with or without chemotherapy followed by radiotherapy on the breast or thoracic wall and the lymph node areas from 5 to 6.5 weeks.

Shorter radiotherapy treatments over 3 weeks for breast cancer without lymph node involvement have been equally effective and have no more side effects in several clinical trials involving several thousand patients. This called hypofractionated radiotherapy has become a standard for breast cancers in the absence of lymph node involvement in postmenopausal women.

The objective of the HypoG01 trial is to evaluate hypofractionated radiotherapy in women who require radiotherapy in the breast or chest wall and lymph node areas by comparing standard over 5 to 6.5 weeks and hypofractionated irradiation over 3 weeks analyzing the possible side effects and in particular the risk of lymphedema (swelling of the arm on the side treated) and the effectiveness of these treatments

03

Conditions studied

  • Breast Cancer Female

Browse trials for

Keywords

  • Breast Cancer pT1-3, pN0-N3, M0
  • Lymph Node Irradiation
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman ≥ 18 years who had radical surgery for invasive breast cancer pT1-3, pN0-N3, M0 with either mastectomy or breast conservation. The patient can be included no matter the status of oestrogen receptor, progesterone receptor, grade, status.
  • 0-2
  • Axillary lymph node dissection of the axilla where the findings give indication for regional nodes radiotherapy to levels +/-I, +/- II, +/-III, +/-IV, +/-interpectoral nodes (Rötter) and +/-the IMN.
  • Sentinel node documenting limited nodal disease without an indication for axillary lymph node dissection according to institutional, national or other trial guidelines are accepted.
  • The patient may be a candidate for a boost to the tumour bed.
  • systemic therapy with chemotherapy, endocrine therapy and anti-HER2 treatment is accepted.
  • Neoadjuvant chemotherapy for downstaging according to institutional or national guidelines is accepted if there is not an indication for a boost in the area of regional nodes after surgery.
  • Primary systemic therapy of an operable breast cancer is accepted.
  • If the patient is not treated with chemotherapy, the patient must be randomized within 8 weeks from last surgery. If the patient has received adjuvant chemotherapy, the patient must be randomized within 4 weeks after the last series of adjuvant chemotherapy or within 42 days from last surgery in case of surgery after neoadjuvant or adjuvant chemotherapy.Breast implants are accepted.
  • Connective tissue disease is allowed if the treating radiation oncologist finds radiotherapy indicated
  • Postoperative infection and/or seroma giving indication for drainage during RT is accepted
  • Women of must agree to use adequate for the duration of study participation and up to 3 months following completion of therapy
  • Signed
  • Affiliated to the Social Security system

Exclusion criteria

Exclusion Criteria:

  • Previous breast cancer or DCIS of the breast.
  • Bilateral breast cancer
  • Patient with previous non-breast with the exception of cancer in complete remission for over 5 years and low risk of recurrence. Patients with the following diseases can be accepted despite less than 5 years disease free interval: carcinoma in situ of the cervix, melanoma in situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin
  • The patient has an indication for boost to 1 or more regional nodes
  • Previous radiotherapy to the chest region
  • Patient enrolled in another therapeutic trial. Observational cohorts are accepted if the collection of data does not interfere with the current trial
  • Pregnant or lactating
  • Conditions indicating that the patient cannot go through the radiation therapy or follow up, or a condition where the treating radiation oncologist thinks the patient should not participate in the trial for example due to language problems.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,265 participants (actual)

Study arms

  • Experimental
    HYPOFRACTIONATED

    40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions per week. If the patient is candidate for a boost it will be provided as follows: * sequential boost with 40 Gy to CTV breast in 15 fractions and 16 Gy to CTV boost in 8 fractions * or simultaneous integrated boost (SIB) with 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fractions

    Radiation: HYPOFRACTIONATED

  • Other
    NORMOFRACTIONATED

    50 Gy / 25 fractions, 2.0 Gy per fraction, 5 fractions per week. If the patient is candidate for a boost it will be provided as follows: * sequential boost with 50 Gy to CTV breast in 25 fractions and 16 Gy to CTV boost in 8 fractions * or simultaneous integrated boost (SIB) with 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fractions

    Radiation: NORMOFRACTIONATED

Interventions

  • RadiationHYPOFRACTIONATED

    40 Gy/ 15 fractions / 3 weeks

    Also known as: Experimental Arm

  • RadiationNORMOFRACTIONATED

    50 Gy/ 25 fractions / 5 weeks

    Also known as: Standard Arm

06

What researchers measure

Primary outcomes

  1. Arm Lymphedema

    Occurrence radiation-induced late morbidity measured as lymphedema of the arm on the treated side at 3 years after adjuvant radiotherapy as follows: At least≥ 10% increased arm circumference measured 15 cm proximal and/or 10 cm distal of the olecranon of the treated side relative to the baseline value, compared to the contralateral side circumference also relative to its baseline value.

    Time frame: At 3 years

Secondary outcomes

  1. Functional Assessment

    Flexion/abduction of the upper arm will be assessed.

    Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

  2. Aesthetics Assessment-FIBROSIS

    Fibrosis as tissue induration, telangiectasia, oedema of the breast/chest wall and dyspigmentation will be evaluated according the LENT-SOMA scoring scale.

    Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

  3. Aesthetics Assessment-BIS SCORE

    The patient evaluates satisfaction on The Body Image Score (BIS) where has been added an extra question regarding clothing habits and furthermore based on the study by Lyngholm et al also 2 more questions regarding the satisfaction with the appearance of the treated breast after breast conservation with and without comparison to the opposite breast as done in the DBCG HYPOII trial. In addition, it will ask if the patient treated with breast conservation has had lipo-feeling injection in the breast during follow up.

    Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

  4. Aesthetics Assessment-Global Cosmestic

    The global cosmetic result after breast conservation will be based on Harris´ 4-point scale modified by Rune Gärtner et al

    Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

  5. CTCAE Toxicity Assessment

    Acute/ late toxicity will be assessed according to the flowchart and performed based on CTCAE V4

    Time frame: Before treatment, every week of treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

  6. RTOG/EORTC Toxicity Assessment

    Acute/ late toxicity will be assessed according to the flowchart and performed based on Toxicity Criteria of RTOG/EORTC

    Time frame: Before treatment, every week of treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

  7. Cancer Related Events

    Cancer related endpoints are secondary endpoints in this trial. It's a composite outcome taking into account all relapse events (locoregional, invasive disease, distant disease), breast-cancer specific survival, and causes of death as defined per DATECAN guidelines. All time to cancer related endpoints are defined as starting from the date of randomization until the event.

    Time frame: 6 months after the last fraction received, every year during 5 years, 10 years

  8. Cost-Utility

    A cost-utility analysis comparing radiotherapy regimens will be performed based on QALYs

    Time frame: Week 3 or week 7 of treatment according the treatment arm and boost realization

  9. Quality of Life QLQ-C30

    Patients' quality of life will be assessed using self-administered questionnaire EORTC QLQ-C30

    Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

  10. Quality of Life EORTC BR23

    Patients' quality of life will be assessed using self-administered questionnaire EORTC BR23

    Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

07

Results

Posted Nov 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneHYPOFRACTIONATEDNORMOFRACTIONATED
Started631629
Completed614607
Not completed1722

Outcome measures

PrimaryArm Lymphedema

Occurrence radiation-induced late morbidity measured as lymphedema of the arm on the treated side at 3 years after adjuvant radiotherapy as follows: At least≥ 10% increased arm circumference measured 15 cm proximal and/or 10 cm distal of the olecranon of the treated side relative to the baseline value, compared to the contralateral side circumference also relative to its baseline value.

Time frame:
At 3 years
Reported as:
Count of participants · Participants
Arm Lymphedema
ParticipantsHYPOFRACTIONATEDNORMOFRACTIONATED
Arm Lymphedema143132
SecondaryFunctional Assessment

Flexion/abduction of the upper arm will be assessed.

Time frame:
Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

Results for this outcome have not been posted.

SecondaryAesthetics Assessment-FIBROSIS

Fibrosis as tissue induration, telangiectasia, oedema of the breast/chest wall and dyspigmentation will be evaluated according the LENT-SOMA scoring scale.

Time frame:
Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

Results for this outcome have not been posted.

SecondaryAesthetics Assessment-BIS SCORE

The patient evaluates satisfaction on The Body Image Score (BIS) where has been added an extra question regarding clothing habits and furthermore based on the study by Lyngholm et al also 2 more questions regarding the satisfaction with the appearance of the treated breast after breast conservation with and without comparison to the opposite breast as done in the DBCG HYPOII trial. In addition, it will ask if the patient treated with breast conservation has had lipo-feeling injection in the breast during follow up.

Time frame:
Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

Results for this outcome have not been posted.

SecondaryAesthetics Assessment-Global Cosmestic

The global cosmetic result after breast conservation will be based on Harris´ 4-point scale modified by Rune Gärtner et al

Time frame:
Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

Results for this outcome have not been posted.

SecondaryCTCAE Toxicity Assessment

Acute/ late toxicity will be assessed according to the flowchart and performed based on CTCAE V4

Time frame:
Before treatment, every week of treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

Results for this outcome have not been posted.

SecondaryRTOG/EORTC Toxicity Assessment

Acute/ late toxicity will be assessed according to the flowchart and performed based on Toxicity Criteria of RTOG/EORTC

Time frame:
Before treatment, every week of treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

Results for this outcome have not been posted.

SecondaryCancer Related Events

Cancer related endpoints are secondary endpoints in this trial. It's a composite outcome taking into account all relapse events (locoregional, invasive disease, distant disease), breast-cancer specific survival, and causes of death as defined per DATECAN guidelines. All time to cancer related endpoints are defined as starting from the date of randomization until the event.

Time frame:
6 months after the last fraction received, every year during 5 years, 10 years

Results for this outcome have not been posted.

SecondaryCost-Utility

A cost-utility analysis comparing radiotherapy regimens will be performed based on QALYs

Time frame:
Week 3 or week 7 of treatment according the treatment arm and boost realization

Results for this outcome have not been posted.

SecondaryQuality of Life QLQ-C30

Patients' quality of life will be assessed using self-administered questionnaire EORTC QLQ-C30

Time frame:
Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

Results for this outcome have not been posted.

SecondaryQuality of Life EORTC BR23

Patients' quality of life will be assessed using self-administered questionnaire EORTC BR23

Time frame:
Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years

Results for this outcome have not been posted.

Adverse events

Collected over The median follow-up time was 4.8 years after randomization.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HYPOFRACTIONATED36/630 (5.7%)21/630 (3.3%)617/630 (97.9%)
NORMOFRACTIONATED51/629 (8.1%)16/629 (2.5%)613/629 (97.5%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventHYPOFRACTIONATEDNORMOFRACTIONATED
ATRIAL FIBRILLATIONCardiac disorders1/6302/629
CARDIAC FAILURECardiac disorders1/6301/629
BREAST HAEMATOMAReproductive system and breast disorders0/6301/629
DEVICE RELATED INFECTIONInfections and infestations0/6301/629
DIABETES MELLITUS INADEQUATE CONTROLMetabolism and nutrition disorders0/6301/629
ERYSIPELASInfections and infestations0/6301/629
FAT NECROSISGeneral disorders0/6301/629
FATIGUEGeneral disorders0/6301/629
IMMUNE THROMBOCYTOPENIC PURPURABlood and lymphatic system disorders0/6301/629
LYMPHOCELEVascular disorders0/6301/629
Most frequent other events
Showing 10 of 13
Most frequent other events
EventHYPOFRACTIONATEDNORMOFRACTIONATED
RADIATION SKIN INJURYInjury, poisoning and procedural complications520/630561/629
PAINGeneral disorders412/630434/629
FATIGUEGeneral disorders401/630401/629
FIBROSISGeneral disorders306/630277/629
PRURITUSSkin and subcutaneous tissue disorders139/630191/629
LYMPHOEDEMAVascular disorders191/630183/629
RESPIRATORY DISORDERSRespiratory, thoracic and mediastinal disorders147/630175/629
DYSPHAGIAGastrointestinal disorders132/630154/629
DYSPIGMENTATIONSkin and subcutaneous tissue disorders107/630123/629
BREAST/NIPPLE OEDEMAReproductive system and breast disorders71/63072/629

Baseline characteristics

Age, Continuous
Age, Continuous(years)HYPOFRACTIONATEDNORMOFRACTIONATEDTotal
Mean58.5 ± 13.158.2 ± 12.558.3 ± 12.8
Age, Continuous
Age, Continuous(years)HYPOFRACTIONATEDNORMOFRACTIONATEDTotal
Mean58.5 ± 13.158.2 ± 12.558.3 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)HYPOFRACTIONATEDNORMOFRACTIONATEDTotal
Female6146071221
Male000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)HYPOFRACTIONATEDNORMOFRACTIONATEDTotal
Count of participants——0
08

Study locations

28 sites
09

References and documents

Publications

  • Rivera S, Ghodssighassemabadi R, Auzac G, Brion T, Kirova Y, Racadot S, Benchalal M, Clavier JB, Charra Brunaud C, Groulier A, Argo-Leignel D, Peignaux K, Benyoucef A, Pasquier D, Guilbert P, Goineau A, Tallet A, Bergeaud M, Lamrani-Ghaouti A, Michiels S; HypoG-01 trialists. 5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial. Lancet. 2026 Mar 7;407(10532):976-987. doi: 10.1016/S0140-6736(25)02597-8. PubMed 41794436 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Dec 2022 and a completion of Sep 2030. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2026, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2016
First posted
Apr 25, 2017
Start
Sep 2016
Primary completionActual
Dec 31, 2022
CompletionEst.
Sep 2030
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 20, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 France)
  • Hôpital Jean Minjoz · Besançon, France
  • Hoptal Henri Mondor · Créteil, France
Show 2 removed
  • Hôpital Jean Minjoz · Besancon, France
  • Hoptal Henri Mondor · Creteil, France
Nov 20, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41794436 ↗
Nov 20, 2026
Secondary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedCancer Related eventsEventsTime frame: 6 months after the last fraction received, every year during 5 years, 10 years
  • RemovedQuality of Life Euroqol EQ-5D5DTime frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41794436 ↗
    2 sites added, 2 sites removed
    Show 2 added (2 France)
    • Hôpital Jean Minjoz · Besançon, France
    • Hoptal Henri Mondor · Créteil, France
    Show 2 removed
    • Hôpital Jean Minjoz · Besancon, France
    • Hoptal Henri Mondor · Creteil, France
    Secondary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedCancer Related eventsEventsTime frame: 6 months after the last fraction received, every year during 5 years, 10 years
    • RemovedQuality of Life Euroqol EQ-5D5DTime frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03127995
Lead sponsor
UNICANCER
Collaborators
National Cancer Institute, France
Responsible party
Sponsor
First posted
Apr 25, 2017
Start date
Sep 2016
Primary completion
Dec 31, 2022
Completion
Sep 2030 (estimated)
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

Sofia RIVERA, M.D, Ph.D
principal investigator · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion